Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.

摘要: Transfusion dependent low risk myelodysplastic syndromes (MDS) patients, eventually develop iron overload. Iron toxicity, via oxidative stress, can damage cellular components and impact organ function. In thalassemia major chelation therapy lowered levels with recovery of cardiac liver functions significant improvement in survival. Several noncontrolled studies show inferior survival MDS patients overload, including an increase transplant-related mortality infection while appears to improve both lower stem cell transplant settings. Collated data are presented on the pathophysiological overload; measuring techniques chelating agents’ positive hematological status overall discussed. Although suggested by retrospective analyses, lack clear prospective beneficial effects morbidity survival, role remains controversial.